A citation-based method for searching scientific literature

Samuel A Wells, Bruce G Robinson, Robert F Gagel, Henning Dralle, James A Fagin, Massimo Santoro, Eric Baudin, Rossella Elisei, Barbara Jarzab, James R Vasselli, Jessica Read, Peter Langmuir, Anderson J Ryan, Martin J Schlumberger. J Clin Oncol 2012
Times Cited: 839



V Subbiah, V Velcheti, B B Tuch, K Ebata, N L Busaidy, M E Cabanillas, L J Wirth, S Stock, S Smith, V Lauriault, S Corsi-Travali, D Henry, M Burkard, R Hamor, K Bouhana, S Winski, R D Wallace, D Hartley, S Rhodes, M Reddy, B J Brandhuber, S Andrews, S M Rothenberg, A Drilon. Ann Oncol 2018
Times Cited: 178




List of shared articles



Times cited

Medullary thyroid cancer - An update.
Laura Fugazzola. Best Pract Res Clin Endocrinol Metab 2022
0

Targeted therapy and drug resistance in thyroid cancer.
Yujie Zhang, Zhichao Xing, Tianyou Liu, Minghai Tang, Li Mi, Jingqiang Zhu, Wenshuang Wu, Tao Wei. Eur J Med Chem 2022
0


Multiple endocrine neoplasia type 2: A review.
Jes Sloth Mathiesen, Grigoris Effraimidis, Maria Rossing, Åse Krogh Rasmussen, Lise Hoejberg, Lars Bastholt, Christian Godballe, Peter Oturai, Ulla Feldt-Rasmussen. Semin Cancer Biol 2022
5

Real-world insights into the efficacy and safety of tyrosine kinase inhibitors against thyroid cancers.
Lingyu Li, Lin Cheng, Ri Sa, Xian Qiu, Libo Chen. Crit Rev Oncol Hematol 2022
1

Resistance to RET targeted therapy in Thyroid Cancer: Molecular basis and overcoming strategies.
María San Román-Gil, Javier Pozas, Diana Rosero-Rodríguez, Jesús Chamorro-Pérez, Álvaro Ruiz-Granados, Ignacio Ruz Caracuel, Enrique Grande, Javier Molina-Cerrillo, Teresa Alonso-Gordoa. Cancer Treat Rev 2022
0

Sporadic Medullary Thyroid Carcinoma: Towards a Precision Medicine.
Antonio Matrone, Carla Gambale, Alessandro Prete, Rossella Elisei. Front Endocrinol (Lausanne) 2022
1

New Horizons: Emerging Therapies and Targets in Thyroid Cancer.
Matthew D Ringel. J Clin Endocrinol Metab 2021
5

Kinase gene fusions: roles and therapeutic value in progressive and refractory papillary thyroid cancer.
Mian Liu, Pei Chen, Hui-Yu Hu, Deng-Jie Ou-Yang, Rooh-Afza Khushbu, Hai-Long Tan, Peng Huang, Shi Chang. J Cancer Res Clin Oncol 2021
3

Anlotinib in Locally Advanced or Metastatic Medullary Thyroid Carcinoma: A Randomized, Double-Blind Phase IIB Trial.
Dapeng Li, Yihebali Chi, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng,[...]. Clin Cancer Res 2021
10

Progress in Treating Advanced Thyroid Cancers in the Era of Targeted Therapy.
Carrie C Lubitz, Peter M Sadow, Gilbert H Daniels, Lori J Wirth. Thyroid 2021
5

ATF4 loss of heterozygosity is associated with poor overall survival in medullary thyroid carcinoma.
Michelle D Williams, Junsheng Ma, Elizabeth G Grubbs, Robert F Gagel, Rozita Bagheri-Yarmand. Am J Cancer Res 2021
0


Targeted activity of the small molecule kinase inhibitor Pz-1 towards RET and TRK kinases.
Marialuisa Moccia, Donglin Yang, Naga Rajiv Lakkaniga, Brendan Frett, Nicholas McConnell, Lingtian Zhang, Annalisa Brescia, Giorgia Federico, Lingzhi Zhang, Paolo Salerno,[...]. Sci Rep 2021
0

Precision therapy for RET-altered cancers with RET inhibitors.
Kyaw Z Thein, Vamsidhar Velcheti, Blaine H M Mooers, Jie Wu, Vivek Subbiah. Trends Cancer 2021
8

Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development.
Debasmita Saha, Katie Rose Ryan, Naga Rajiv Lakkaniga, Baku Acharya, Noemi Garcia Garcia, Erica Lane Smith, Brendan Frett. J Med Chem 2021
1

[Molecular genotyping in refractory thyroid cancers in 2021: When, how and why? A review from the TUTHYREF network].
Christelle de la Fouchardière, Johanna Wassermann, Fabien Calcagno, Stéphane Bardet, Abir Al Ghuzlan, Isabelle Borget, Françoise Borson Chazot, Christine Do Cao, Camille Buffet, Slimane Zerdoud,[...]. Bull Cancer 2021
0